| ￥1200 | |
| A03898 | |
|
|
|
|
|
|
|
|
|
| Specificity | This product is specific to IFITM3 |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human IFITM3 |
| Species Reactivity | Human |
| Conjugate | Unconjugated |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||||||||||
|
|||||||||||||
| Form | Liquid |
| Storage Buffer | Supplied in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol. |
| Storage Instructions | Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed. |
| Purification | Affinity-chromatography |
| Isotype | Rabbit IgG |
| Clonality | Monoclonal |
| Target Background | IFN-induced antiviral protein that mediates cellular innate immunity to at least three major human pathogens, namely influenza A H1N1 virus, West Nile virus (WNV), and dengue virus (WNV), by inhibiting the early step(s) of replication. |
| Synonyms | Fragilis; IFITM3; Interferon inducible; IP15; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
